Florian Naudet
@floriannaudet.bsky.social
Meta-researcher, Clinician, Professor at Rennes University, Senior member at Institut Universitaire de France, affiliate at METRICStanford. ORCID: 0000-0003-3760-3801
Posts are my own.
Website: https://restores.univ-rennes.fr/
Posts are my own.
Website: https://restores.univ-rennes.fr/
Pinned
Florian Naudet
@floriannaudet.bsky.social
· Jan 23
Esketamine for depression, registered reports, and alcohol use disorder | Metascience Matters #2
YouTube video by Metascience Matters
www.youtube.com
Super happy to be interviewed by Randy Ellis for his Metascience Matters podcast 🎙️
Really fun and open discussion. Less about meta-science in the narrow sense, and more about science as it’s actually practiced, plus the everyday realities of academic life.
Thanks Randy for the great conversation!
Really fun and open discussion. Less about meta-science in the narrow sense, and more about science as it’s actually practiced, plus the everyday realities of academic life.
Thanks Randy for the great conversation!
🚨 paper alert 🚨
« Open Science Policies and Practices Among Medical Journals » led by Constant Vinatier.
jamanetwork.com/journals/jam...
« Open Science Policies and Practices Among Medical Journals » led by Constant Vinatier.
jamanetwork.com/journals/jam...
Open Science Policies and Practices Among Medical Journals
This cross-sectional study evaluates which open science practices have been adopted by leading general medical journals and whether automated tools can assess article-level adherence.
jamanetwork.com
September 4, 2026 at 6:10 PM
🚨 paper alert 🚨
« Open Science Policies and Practices Among Medical Journals » led by Constant Vinatier.
jamanetwork.com/journals/jam...
« Open Science Policies and Practices Among Medical Journals » led by Constant Vinatier.
jamanetwork.com/journals/jam...
Reposted by Florian Naudet
Reposted by Florian Naudet
7. Posted on PubPeer:
pubpeer.com/publications...
M/SDs also appear to be GRIM/GRIMMER inconsistent, but this needs a more thorough check
pubpeer.com/publications...
M/SDs also appear to be GRIM/GRIMMER inconsistent, but this needs a more thorough check
PubPeer - Efficacy and safety evaluation of intravenous esketamine in...
There are comments on PubPeer for publication: Efficacy and safety evaluation of intravenous esketamine in alleviating perioperative depressive symptoms in Parkinson’s disease: a randomized controlled...
pubpeer.com
September 4, 2026 at 5:59 AM
7. Posted on PubPeer:
pubpeer.com/publications...
M/SDs also appear to be GRIM/GRIMMER inconsistent, but this needs a more thorough check
pubpeer.com/publications...
M/SDs also appear to be GRIM/GRIMMER inconsistent, but this needs a more thorough check
Reposted by Florian Naudet
1. Rant: with the help of BMC Journals, the literature is flooded with potentially fraudulent ketamine/esketamine studies.
I just came across this one. SMD = 3.8 on day 7, when administered during anesthesia. Absurd!
I just came across this one. SMD = 3.8 on day 7, when administered during anesthesia. Absurd!
Efficacy and safety evaluation of intravenous esketamine in alleviating perioperative depressive symptoms in Parkinson’s disease: a randomized controlled trial - BMC Anesthesiology
Objective Depressive symptoms frequently afflict individuals with Parkinson’s disease (PD). The current study was consequently conducted to determine the efficacy of low-dose intravenous esketamine in...
link.springer.com
September 3, 2026 at 8:52 AM
1. Rant: with the help of BMC Journals, the literature is flooded with potentially fraudulent ketamine/esketamine studies.
I just came across this one. SMD = 3.8 on day 7, when administered during anesthesia. Absurd!
I just came across this one. SMD = 3.8 on day 7, when administered during anesthesia. Absurd!
Reposted by Florian Naudet
2. Study says it followed the Helsinki Declaration, but it was registered retrospectively. The Helsinki Declaration requires prospective registration.
September 3, 2026 at 8:52 AM
2. Study says it followed the Helsinki Declaration, but it was registered retrospectively. The Helsinki Declaration requires prospective registration.
Reposted by Florian Naudet
3. "a recent large-scale meta-analysis (67 RCTs, n= 11,553) concluded that intravenous administration, the route used in our study, is the most effective for improving depressive symptoms and preventing postoperative depression, though it may carry a higher risk of dizziness [7]"
Ref #7: mice study!
Ref #7: mice study!
September 3, 2026 at 8:52 AM
3. "a recent large-scale meta-analysis (67 RCTs, n= 11,553) concluded that intravenous administration, the route used in our study, is the most effective for improving depressive symptoms and preventing postoperative depression, though it may carry a higher risk of dizziness [7]"
Ref #7: mice study!
Ref #7: mice study!
Reposted by Florian Naudet
4. Detected in about 30Minutes. I assume that many more oddities will occur when taking a closer look.
@floriannaudet.bsky.social @ianhussey.mmmdata.io
@floriannaudet.bsky.social @ianhussey.mmmdata.io
September 3, 2026 at 9:29 AM
4. Detected in about 30Minutes. I assume that many more oddities will occur when taking a closer look.
@floriannaudet.bsky.social @ianhussey.mmmdata.io
@floriannaudet.bsky.social @ianhussey.mmmdata.io
Reposted by Florian Naudet
5. This is the p-value for the comparison of depression between esketamine and placebo at t3:
0.0000000000000000008
SMD = 3.77 (95% CI 2.88 to 4.67)
0.0000000000000000008
SMD = 3.77 (95% CI 2.88 to 4.67)
September 3, 2026 at 11:08 AM
5. This is the p-value for the comparison of depression between esketamine and placebo at t3:
0.0000000000000000008
SMD = 3.77 (95% CI 2.88 to 4.67)
0.0000000000000000008
SMD = 3.77 (95% CI 2.88 to 4.67)
Reposted by Florian Naudet
6. "The trial protocol was prospectively registered with the Chinese Clinical Trial Registry" versus "An additional limitation of this study is the retrospective trial registration.when in fact it was done retrospectively"
September 3, 2026 at 2:29 PM
6. "The trial protocol was prospectively registered with the Chinese Clinical Trial Registry" versus "An additional limitation of this study is the retrospective trial registration.when in fact it was done retrospectively"
Reposted by Florian Naudet
Research is so much more difficult when you care about research integrity. This is why it will never be a priority for most researchers. Researchers benefit from lax standards.
September 3, 2026 at 8:09 AM
Research is so much more difficult when you care about research integrity. This is why it will never be a priority for most researchers. Researchers benefit from lax standards.
Peer review of the day: Is it possible that researchers pooled the baseline characteristics of clinical trials, thinking they were actually analyzing the efficacy of a treatment. and, on top of that, pooled the primary publication of a trial together with its secondary publications?
Answer: YES
Answer: YES
August 27, 2026 at 12:16 PM
Peer review of the day: Is it possible that researchers pooled the baseline characteristics of clinical trials, thinking they were actually analyzing the efficacy of a treatment. and, on top of that, pooled the primary publication of a trial together with its secondary publications?
Answer: YES
Answer: YES
Reposted by Florian Naudet
Choice of estimands and estimators affected the interpretation of results for some outcomes in a cluster-randomised trial (RESTORE) due to informative cluster size - Journal of Clinical Epidemiology www.jclinepi.com/article/S089...
Choice of estimands and estimators affected the interpretation of results for some outcomes in a cluster-randomised trial (RESTORE) due to informative cluster size
In cluster-randomised trials (CRTs), different estimands can be targeted, such as
the individual- or cluster-average effect. These two estimands can differ in magnitude
when outcomes or treatment effe...
www.jclinepi.com
August 24, 2026 at 7:28 PM
Choice of estimands and estimators affected the interpretation of results for some outcomes in a cluster-randomised trial (RESTORE) due to informative cluster size - Journal of Clinical Epidemiology www.jclinepi.com/article/S089...
A new editorial (in French) published in La Revue de Médecine Interne by Alexandre Terré, Marie-France Mamzer and I, examines the avacopan (Tavneos®) case and the serious questions it raises about the integrity and oversight of clinical research.
authors.elsevier.com/c/1nfgAubUqz...
authors.elsevier.com/c/1nfgAubUqz...
August 24, 2026 at 4:26 PM
A new editorial (in French) published in La Revue de Médecine Interne by Alexandre Terré, Marie-France Mamzer and I, examines the avacopan (Tavneos®) case and the serious questions it raises about the integrity and oversight of clinical research.
authors.elsevier.com/c/1nfgAubUqz...
authors.elsevier.com/c/1nfgAubUqz...
🚨 New preprint on nepotistic editors 🚨
How frequently do journal editors publish research articles in the journals they oversee? Our new preprint led by the great Cedric Lemarchand provides some interesting data from biomedical research.
www.medrxiv.org/content/10.6...
How frequently do journal editors publish research articles in the journals they oversee? Our new preprint led by the great Cedric Lemarchand provides some interesting data from biomedical research.
www.medrxiv.org/content/10.6...
Editors and research articles: a retrospective study of self-publication in biomedical research
Objective In 2021, a large-scale survey highlighted that in a subset of biomedical journals, a few authors –often serving on the editorial board– published disproportionately and experienced shorter a...
www.medrxiv.org
August 24, 2026 at 3:03 PM
🚨 New preprint on nepotistic editors 🚨
How frequently do journal editors publish research articles in the journals they oversee? Our new preprint led by the great Cedric Lemarchand provides some interesting data from biomedical research.
www.medrxiv.org/content/10.6...
How frequently do journal editors publish research articles in the journals they oversee? Our new preprint led by the great Cedric Lemarchand provides some interesting data from biomedical research.
www.medrxiv.org/content/10.6...
New paper published in JCE: « The Erosion of Proof in Paradigm Transitions: The Rise of Narrative Rationality in Health Technology Assessment. » Lega JC, Gougeon A, Michal C, Provencher S, Naudet F, Falissard B, Chevrette C, Boussageon R
jclinepi.com/retrieve/pii...
jclinepi.com/retrieve/pii...
jclinepi.com
August 13, 2026 at 4:12 PM
New paper published in JCE: « The Erosion of Proof in Paradigm Transitions: The Rise of Narrative Rationality in Health Technology Assessment. » Lega JC, Gougeon A, Michal C, Provencher S, Naudet F, Falissard B, Chevrette C, Boussageon R
jclinepi.com/retrieve/pii...
jclinepi.com/retrieve/pii...
Reposted by Florian Naudet
🚨 1. Can changed trial characteristics explain fluoxetine's loss of efficacy for pediatric depression?
New paper by @floriannaudet.bsky.social @richlyus.bsky.social and me is out.
It is a secondary meta-regression on an already existing meta-analysis.
Why was this important?
->
New paper by @floriannaudet.bsky.social @richlyus.bsky.social and me is out.
It is a secondary meta-regression on an already existing meta-analysis.
Why was this important?
->
Can fluoxetine’s diminished efficacy in pediatric depression be explained by study sites, baseline severity, age, and psychological interventions? A secondary exploratory meta-regression.
Fluoxetine’s efficacy estimates in pediatric depression trials have declined to the range of placebo equivalence. We investigated whether changes in t…
www.sciencedirect.com
August 13, 2026 at 4:07 PM
🚨 1. Can changed trial characteristics explain fluoxetine's loss of efficacy for pediatric depression?
New paper by @floriannaudet.bsky.social @richlyus.bsky.social and me is out.
It is a secondary meta-regression on an already existing meta-analysis.
Why was this important?
->
New paper by @floriannaudet.bsky.social @richlyus.bsky.social and me is out.
It is a secondary meta-regression on an already existing meta-analysis.
Why was this important?
->
Reposted by Florian Naudet
OSF is Changing!
Starting Nov 16, 2026, no new projects or child components of existing projects can be created on OSF
After Feb 19, 2027, all public and private OSF projects will become read-only
Learn more at www.cos.io/osf-changes
@cos.io @briannosek.bsky.social
Starting Nov 16, 2026, no new projects or child components of existing projects can be created on OSF
After Feb 19, 2027, all public and private OSF projects will become read-only
Learn more at www.cos.io/osf-changes
@cos.io @briannosek.bsky.social
OSF Changes | Center for Open Science
We are preparing substantial changes to OSF that will reduce its functionality, focus OSF on its unique strengths, and move toward an integrated model with complementary services. As part of that shif...
www.cos.io
August 12, 2026 at 7:49 PM
OSF is Changing!
Starting Nov 16, 2026, no new projects or child components of existing projects can be created on OSF
After Feb 19, 2027, all public and private OSF projects will become read-only
Learn more at www.cos.io/osf-changes
@cos.io @briannosek.bsky.social
Starting Nov 16, 2026, no new projects or child components of existing projects can be created on OSF
After Feb 19, 2027, all public and private OSF projects will become read-only
Learn more at www.cos.io/osf-changes
@cos.io @briannosek.bsky.social
🔥 New SHARE-CTD paper in JCE co-led by the 2 brilliant Ka Hin Tai and Giulia Varvarà:
Data sharing policies, requirements, and support from public and private clinical trial sponsors: a survey on top sponsors of clinical trials in Europe
www.jclinepi.com/article/S089...
Data sharing policies, requirements, and support from public and private clinical trial sponsors: a survey on top sponsors of clinical trials in Europe
www.jclinepi.com/article/S089...
www.jclinepi.com
August 11, 2026 at 5:35 AM
🔥 New SHARE-CTD paper in JCE co-led by the 2 brilliant Ka Hin Tai and Giulia Varvarà:
Data sharing policies, requirements, and support from public and private clinical trial sponsors: a survey on top sponsors of clinical trials in Europe
www.jclinepi.com/article/S089...
Data sharing policies, requirements, and support from public and private clinical trial sponsors: a survey on top sponsors of clinical trials in Europe
www.jclinepi.com/article/S089...
Three reasons to be happy today.
1/ I'm on holiday (long overdue)... 🏝️
1/ I'm on holiday (long overdue)... 🏝️
August 1, 2026 at 7:03 PM
Three reasons to be happy today.
1/ I'm on holiday (long overdue)... 🏝️
1/ I'm on holiday (long overdue)... 🏝️
Reposted by Florian Naudet
Wunderbar!
July 28, 2026 at 8:33 PM
Wunderbar!
Long day at work. Not the easiest one. Not the worst ever...
Now it's evening, I'm back on the SHARE-CTD Datathon 2 writting, with some good music that reminds me of California. Not a bad way to end the day.
The endless teaser continues... 😉
www.deezer.com/fr/album/130...
Now it's evening, I'm back on the SHARE-CTD Datathon 2 writting, with some good music that reminds me of California. Not a bad way to end the day.
The endless teaser continues... 😉
www.deezer.com/fr/album/130...
Dark Necessities
Red Hot Chili Peppers - album - 2016 - 1 titre
www.deezer.com
July 28, 2026 at 8:31 PM
Long day at work. Not the easiest one. Not the worst ever...
Now it's evening, I'm back on the SHARE-CTD Datathon 2 writting, with some good music that reminds me of California. Not a bad way to end the day.
The endless teaser continues... 😉
www.deezer.com/fr/album/130...
Now it's evening, I'm back on the SHARE-CTD Datathon 2 writting, with some good music that reminds me of California. Not a bad way to end the day.
The endless teaser continues... 😉
www.deezer.com/fr/album/130...
Reposted by Florian Naudet
New preprint led by Tala Jajieh from the ResToRes project.
By analysing RCTs with confirmed data fabrication, our new preprint reveals that most zombie trials arise from monocentric, recurrent patterns of misconduct and often remain undetected for many years.
www.medrxiv.org/content/10.6...
By analysing RCTs with confirmed data fabrication, our new preprint reveals that most zombie trials arise from monocentric, recurrent patterns of misconduct and often remain undetected for many years.
www.medrxiv.org/content/10.6...
July 25, 2026 at 7:28 PM
New preprint led by Tala Jajieh from the ResToRes project.
By analysing RCTs with confirmed data fabrication, our new preprint reveals that most zombie trials arise from monocentric, recurrent patterns of misconduct and often remain undetected for many years.
www.medrxiv.org/content/10.6...
By analysing RCTs with confirmed data fabrication, our new preprint reveals that most zombie trials arise from monocentric, recurrent patterns of misconduct and often remain undetected for many years.
www.medrxiv.org/content/10.6...
July 25, 2026 at 6:57 AM
New preprint led by Tala Jajieh from the ResToRes project.
By analysing RCTs with confirmed data fabrication, our new preprint reveals that most zombie trials arise from monocentric, recurrent patterns of misconduct and often remain undetected for many years.
www.medrxiv.org/content/10.6...
By analysing RCTs with confirmed data fabrication, our new preprint reveals that most zombie trials arise from monocentric, recurrent patterns of misconduct and often remain undetected for many years.
www.medrxiv.org/content/10.6...
Reposted by Florian Naudet
4. The editorial is IMO another example of wishful thinking in biological psychiatry, providing an outlook of finding moderators to allow precision psychiatry. There are many reasons for being humble here:
bsky.app/profile/ploe...
bsky.app/profile/ploe...
1/ About personalized medicine/psychiatry:
a new paper by @JonasRueppel, with a meta-view on the issue and insights obtained by interviewing psychiatrists
https://journals.sagepub.com/doi/10.1177/0162243919845049
Longer thread with some background info
a new paper by @JonasRueppel, with a meta-view on the issue and insights obtained by interviewing psychiatrists
https://journals.sagepub.com/doi/10.1177/0162243919845049
Longer thread with some background info
July 23, 2026 at 6:49 AM
4. The editorial is IMO another example of wishful thinking in biological psychiatry, providing an outlook of finding moderators to allow precision psychiatry. There are many reasons for being humble here:
bsky.app/profile/ploe...
bsky.app/profile/ploe...
Reposted by Florian Naudet
3. The editorial is about a individual patient meta-analysis of placebo-controlled trials (see thread below). This is the appropriate way to look at treatment effect heterogeneity.
bsky.app/profile/ploe...
bsky.app/profile/ploe...
1. New IPD meta-analysis on antidepressants (ADs) to treat depression in children & adolescents. This is massive work and potentially important given the poor efficacy of ADs: < 2 points on the Childhood depression rating scale (CDRS) which ranges from 17 to 113 with a suggested MCID of 5 points ->
An Individual Participant Data Analysis: Optimizing Pharmacological Treatment in Children and Adolescents With Major Depressive Disorder
The influence of individual characteristics on antidepressant efficacy and tolerability
in pediatric major depressive disorder (MDD) remains unclear. This study aimed to
characterize subgroup-specific...
www.jaacap.org
July 23, 2026 at 6:49 AM
3. The editorial is about a individual patient meta-analysis of placebo-controlled trials (see thread below). This is the appropriate way to look at treatment effect heterogeneity.
bsky.app/profile/ploe...
bsky.app/profile/ploe...